Month: April 2021

NORBIT ASA – Notice of Annual General Meeting on 4 May 2021

Written by Customer Service on April 9, 2021. Posted in Public Companies.

Trondheim, 9 April 2021: The Annual General Meeting of NORBIT ASA will be held on Tuesday 4 May 2021 at 4:00 pm at the company’s headquarter in Stiklestadveien 1, 7041 Trondheim, Norway. Due to the COVID-19 situation and in order to comply with the advice of the authorities, NORBIT’s shareholders and other stakeholders are urged not to physically attend the meeting, but rather to use the available means to vote electronically or submit a proxy form prior to the meeting. Attached please find the following documents:The notice of the general meeting, including the proposed resolutions and attendance and proxy forms The proposal from the nomination committee for the general meeting The guidelines for remuneration of the executive management of the companyAll documents to be processed in the meeting, including access to electronic registration,...

Nyxoah Reports Full Year 2020 Results

Written by Customer Service on April 9, 2021. Posted in Earnings Releases And Operating Results.

Nyxoah Reports Full Year 2020 Results Conference call and webcast today at 3pm CET / 9am ET Mont-Saint-Guibert, Belgium – 9 April 2021 – Nyxoah SA (Euronext Brussels: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the full year ended December 31, 2020. Olivier Taelman, Chief Executive Officer of Nyxoah, said: “2020 was a year marked by key accomplishments for Nyxoah, with important milestones showing focused execution across business units. Despite the Covid-19 pandemic, the impact on Nyxoah’s activities was limited and our manufacturing facilities remained operational, with sufficient production to meet our needs.” Key PointsFinancial25M€ round onboarding...

Nyxoah présente ses résultats pour l’exercice 2020

Written by Customer Service on April 9, 2021. Posted in Earnings Releases And Operating Results.

Nyxoah présente ses résultats pour l’exercice 2020 Visioconférence et webcast aujourd’hui à 15 h (heure de Paris) /9 h ET Mont-Saint-Guibert, Belgique – 9 avril 2021 – Nyxoah SA (Euronext : NYXH) (« Nyxoah » ou la « Société ») opère dans le secteur des technologies médicales et se concentre sur le développement et la commercialisation de solutions innovantes destinées à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). Elle annonce aujourd’hui ses résultats financiers et d’exploitation pour l’exercice ayant pris fin le 31 décembre 2020. Olivier Taelman, Chief Executive Officer de Nyxoah, a déclaré : « 2020 a été une année charnière pour Nyxoah. Nous avons atteint des objectifs importants qui reflètent une exécution ciblée dans les différentes unités commerciales. Malgré la pandémie de Covid-19, les répercussions sur les activités...

LIZHI Inc. Announces Pricing of $30.0 Million Registered Direct Offering

Written by Customer Service on April 9, 2021. Posted in Public Companies.

GUANGZHOU, China, April 09, 2021 (GLOBE NEWSWIRE) — LIZHI INC. (“LIZHI” or the “Company”) (NASDAQ: LIZI), a leading online UGC audio community and interactive audio entertainment platform in China, announced today that it has entered into a securities purchase agreement with a certain institutional investor to purchase $30,000,002 worth of its American Depositary Shares (“ADS”) and warrants in a registered direct offering. Under the terms of the securities purchase agreement, the Company has agreed to sell 3,685,504 ADSs and warrants to purchase 2,764,128 ADSs. The warrants will be exercisable immediately upon the date of issuance and have an exercise price of $8.14. The warrants will expire five years from the date of issuance. The purchase price for one ADS and three-quarters corresponding warrant will be $8.14. The gross proceeds...

Schweiter Technologies extends PET production capacity and takes stake in JMB Wind Engineering

Written by Customer Service on April 9, 2021. Posted in Public Companies.

Steinhausen, April 9, 2021 – Schweiter Technologies is strengthening its 3A Composites core materials business by a PET foam production extension in Poland and has simultaneously signed and closed an agreement to acquire 40% of JMB Wind Engineering (“JMB”). JMB (www.jmbwind.com), based in Goleniów, Poland, is a leading company in core materials kit design and production, mainly for wind turbines, with operations in Poland and Portugal. After the successful start of a PET production line in China in 2020, to expand the capacities in Europe another satellite PET production site is planned for at JMB in Poland, which offers ideal production facilities and logistics. JMB will continue to operate as a stand-alone entity, with the existing management team continuing to run the business from its bases in Poland and Portugal. The minority stake...

Schweiter Technologies erweitert PET-Produktionskapazität und beteiligt sich an JMB Wind Engineering

Written by Customer Service on April 9, 2021. Posted in Public Companies.

Steinhausen, 9. April 2021 – Schweiter Technologies stärkt das 3A Composites Kernmaterial-Geschäft durch eine PET-Schaum Produktionserweiterung in Polen und hat eine Vereinbarung zum Erwerb von 40% der Anteile von JMB Wind Engineering („JMB“) unterzeichnet und gleichzeitig vollzogen. JMB (www.jmbwind.com) mit Sitz in Goleniów, Polen, ist ein führendes Unternehmen in der Entwicklung und Produktion von Kernmaterial-Kits schwergewichtig für Windkraftanlagen, mit Niederlassungen in Polen und Portugal. Nach der erfolgreichen Inbetriebnahme einer PET-Produktionslinie in China im Jahr 2020 ist zum Ausbau der Kapazitäten in Europa bei JMB in Polen ein weiterer PET-Produktionsstandort geplant, der ideale Produktionsmöglichkeiten und Logistikvorteile bietet. JMB wird weiterhin als eigenständige Gesellschaft operieren und das bestehende Managementteam...

CORRECTION — Ultra Resources Inc. Closes Private Placement

Written by Customer Service on April 9, 2021. Posted in Public Companies.

VANCOUVER, British Columbia, April 09, 2021 (GLOBE NEWSWIRE) — In a release issued under the same headline on Wednesday April 7, 2021 by Ultra Resources Inc. (TSX-V: ULT), please note that the finders fees have been corrected to $66,322 cash and 602,928 finders warrants. The corrected release follows: Ultra Resources Inc. (TSX-V: ULT) (“Ultra Resources” or the “Company”) is pleased to announce that it has closed a non-brokered private placement of 9,438,250 units at $0.11 per unit for total gross proceeds of $1,038,208. Each Unit is comprised of one common share and one-half non-transferable common share purchase warrant (“Warrant”). Each whole Warrant will entitle the holder to purchase an additional common share of the Company at an exercise price of $0.20 per share for a period of one year from closing of the private...

Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi’s novel investigational IL-2

Written by Customer Service on April 9, 2021. Posted in Public Companies.

Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi’s novel investigational IL-2Early clinical results are consistent with preclinical studies and suggest THOR-707 (SAR444245) may promote an anti-tumor immune response without alpha-mediated side effects, both alone and in combination with anti-PD-1 THOR-707, a precisely PEGylated, engineered version of IL-2 built on Sanofi’s Synthorin™ technology platform, is being studied in a trial of adults with advanced or metastatic solid tumorsPARIS – April 9, 2021 – Interim data from a first-in-human trial evaluating the safety, therapeutic activity and maximum tolerable dose of THOR-707 (SAR444245), a highly differentiated not-alpha interleukin-2 (IL-2) candidate, as a monotherapy and in combination with anti-PD-1, will be presented Saturday, April...

Des données cliniques intermédiaires de dernière minute valident le profil « non-alpha » de THOR-707 (SAR444245), nouvelle IL-2 expérimentale de Sanofi

Written by Customer Service on April 9, 2021. Posted in Public Companies.

Des données cliniques intermédiaires de dernière minute valident le profil « non-alpha » de THOR-707 (SAR444245), nouvelle IL-2 expérimentale de SanofiLes résultats cliniques précoces confortent ceux des études précliniques et donnent à penser que THOR-707 (SAR444245), en monothérapie ou en association avec un anti-PD-1, pourrait induire une réponse immunitaire antitumorale, sans les effets secondaires médiés par la chaîne alpha. THOR-707, une version modifiée d’IL-2, PEGylée avec précision, développé avec la plateforme technologique Synthorin™ de Sanofi, fait l’objet d’essais cliniques chez des adultes porteurs de tumeurs solides au stade avancé ou métastatiquesPARIS – Le 9 avril 2021 – Les données intermédiaires d’un premier essai chez l’homme évaluant l’innocuité, l’activité thérapeutique et la dose maximale...

Progress Software Announces Upsize and Pricing of Convertible Senior Notes Offering

Written by Customer Service on April 9, 2021. Posted in Public Companies.

BEDFORD, Mass., April 08, 2021 (GLOBE NEWSWIRE) — Progress Software Corporation (NASDAQ: PRGS) (“Progress”) today announced the pricing of its private offering of $325.0 million aggregate principal amount of 1.00% Convertible Senior Notes due 2026 (the “Notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Progress also granted the initial purchasers of the Notes an option to purchase up to an additional $50.0 million aggregate principal amount of the Notes, for settlement within a 13-day period beginning on, and including, the first date on which the Notes are issued. The aggregate principal amount of the offering was increased from the previously announced offering size of $300.0 million (or $345.0 million if the initial...

Month: April 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals